Anemia and the Low-risk MDS Patient: The Current Landscape and Future Directions

Anemia and the Low-risk MDS Patient: The Current Landscape and Future Directions
Anemia and the Low-risk MDS Patient: The Current Landscape and Future Directions
CME, CPE
Shyamala C. Navada, MD, MSCR
Release Date: March 09, 2020
Expiration Date: March 09, 2021

Anemia is the most common cytopenia in patients with lower-risk MDS. In this activity, Dr. Shyamala Navada describes this impact on outcomes and prognosis of patients while also identifying therapeutic strategies for treating anemia which aim to reduce transfusion burden. She will also review the investigational agents currently in clinical development that are likely to provide new options for lower-risk MDS.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.
Begin, Earn CreditView Only, No CreditGet Certificate
 

MediCom Worldwide, Inc. would like to thank Celgene Corporation and Onconova Therapeutics Inc. for their educational support of ManagingMDS.com

©2020 MediCom Worldwide, Inc. All rights reserved